

7-5/2013/EU/WC-0140
Government of India
Directorate General of Health Services
Central Drugs Standard Control Organisation
(International Cell)

FDA Bhawan, Kotla Road,
New Delhi-110002

Dated **20 JUN 2025**

To

**M/s Cipla Ltd.,
D-22, M.I.D.C, Industrial Area,
Kurkumbh, Taluka – Daund, Pune-413 802,
Maharashtra State, India.**

SUB:- Written Confirmation of **M/s Cipla Ltd., D-22, M.I.D.C, Industrial Area, Kurkumbh, Taluka – Daund, Pune-413 802, Maharashtra State, India** as per requirement of EU for import of active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC from India-Reg.

Sir,

Please refer to your online application no. WC/RE/2025/9920 dated 18-FEB-2025 submitted to CDSCO, West Zone office, and the recommendation received from DDC (I), West Zone on the above noted subject.

Written Confirmation as required for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC from India is herewith granted subject to the following conditions:-

1. The Active Pharmaceutical Ingredients shall confirm to Good Manufacturing Practices mentioned in the EU directives or other equivalent (GMP of WHO/ICH Q7).
2. The manufacturer is subject to regular, strict and transparent controls and to the effective enforcement of Good Manufacturing Practice, including repeated and unannounced inspections, so as to ensure a protection of public health equivalent to that in the EU.
3. The manufacturer is required to follow the Guidance document for Issue of Written Confirmation as issued by CDSCO.
4. Written Confirmation shall be produced by the Authorized Exporter as and when required by the Drug Regulatory Authority.
5. The Written Confirmation will be withdrawn in the events of non-compliance of Standards.

6. This Written Confirmation, unless it is sooner suspended or cancelled, shall be valid for a period of three years.
7. In the event of any Non-Compliance observed during inspections conducted by Local or International Drug Authorities, the same shall be forwarded to this office within 7 days of receipt of report.
8. In the event of any drug found not of standard quality, the same shall be reported to this office within 7 days of receipt of report.
9. The manufacturer is required to comply with the provisions of GSR 20(E), dated 18.01.2022.
10. The manufacturer shall obtain NOC from the respective CDSCO office on case to case basis for manufacture of active substance for export purpose, if active substance is falling under Unapproved/Banned/ New drug in India.

Please note that Written Confirmation issued is liable to be suspended / cancelled, if any of the conditions stipulated above are not complied with or in case of violation of the provisions of the Drugs & Cosmetics Act, 1940 and the Rules thereunder as the case may be.

Please acknowledge the receipt.

Annexure No.	No. of Products	Date of Issue	Valid Upto
--	--	20 JUN 2025	02.07.2028
01	16	20 JUN 2025	02.07.2028

Yours faithfully,

Chandrashekar
20/06/25

(Ranga Chandrashekar)
Joint Drugs Controller (India)

चंद्रशेखर रंगा/Chandrashekar Ranga
संयुक्त औषधि नियंत्रक (भारत) / Joint Drugs Controller (India)
केंद्रीय औषधि मानक नियंत्रण संगठन (मुख्यालय), स्वास्थ्य सेवा विभाग
C.D.S.C.O.(HQ), Dte. General of Health Services
स्वास्थ्य और परिवार कल्याण विभाग / Ministry of Health and Family Welfare
एफ.डी.ए. भवन, कोटला रोड, नई दिल्ली-110002 / FDA Bhawan, Kotla Road, New Delhi-110002



Written confirmation for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC

1. Name and address of site: M/s Cipla Ltd.,
D-22, M.I.D.C, Industrial Area,
Kurkumbh, Taluka – Daund, Pune- 413 802,
Maharashtra State, India

2. Manufacturer's licence number: 25-PD/201 & 28-PD/123

Regarding the manufacturing plant under (1) of the following Active substance(s) exported to the EU for medicinal products for human use

List of API(s):

And as per the annexure(s) enclosed.

The issuing Regulatory Authority hereby confirms that:

The standards of good manufacturing practice applicable to this manufacturing plant are at least equivalent to those laid down in the EU (= GMP of WHO/ICH Q7);

The manufacturing plant is subject to regular, strict and transparent controls and to the effective enforcement of good manufacturing practice, including repeated and unannounced inspections, so as to ensure a protection of public health at least equivalent to that in the EU; and

In the event of findings relating to non-compliance, information on such findings is supplied by the exporting third country without delay to the EU.

Date of Inspection of the plant: 07.10.2024 & 08.10.2024

The Written Confirmation remains valid until: 02.07.2028

The authenticity of this written confirmation may be verified with the issuing regulatory authority.

This written confirmation is without prejudice to the responsibilities of the manufacturer to ensure the quality of the medicinal product in accordance with Directive 2001/83/EC.

Address of the issuing regulatory authority: Central Drugs Standard Control Organisation

FDA Bhawan, Kotla Road,
New Delhi- 110 002, India

Name and function of responsible person: Ranga Chandrashekar,
Joint Drugs Controller (India)


E-mail: ranga.cs@cdsco.nic.in;

Telephone no.: +91-11-23236965

Fax no.: +91-11-23236973

Signature
चंद्रशेखर रंगा/Chandrashekar Ranga
20/06/25

Joint Drugs Controller (India)
केंद्रीय औषधि नियंत्रक (भारत) / Joint Drugs Controller (India)
C.D.S.C.O(HQ), Dte. General of Health Services
स्वास्थ्य और परिवार कल्याण मंत्रालय / Ministry of Health and Family W
एफ.डी.ए. भवन, कोटला रोड, नई दिल्ली-110002 / FDA Bhawan, Kotla Road, New Delhi



Stamp of the authority and date

20 JUN 2025



GOVERNMENT OF INDIA
MINISTRY OF HEALTH & FAMILY WELFARE
Central Drugs Standard Control Organization

Annexure-01
WC-0140
CERTIFICATE NO. :

Written confirmation for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC

1. Name and address of site: M/s Cipla Ltd.,
D-22, M.I.D.C, Industrial Area,
Kurkumbh, Taluka – Daund, Pune 413 802,
Maharashtra State, India

List of API(s):

S. No.	Active substance (s)	Activity(ies)
1.	Abacavir Sulfate BP/USP/Ph.Eur.	Manufacturing & Packing
2.	Anhydrous Nevirapine BP/USP/Ph.Eur.	Manufacturing & Packing
3.	Cyproterone Acetate BP/Ph.Eur.	Manufacturing & Packing
4.	Deferasirox IH	Manufacturing & Packing
5.	Dolutegravir Sodium IH	Manufacturing & Packing
6.	Empagliflozin IH	Manufacturing & Packing
7.	Emtricitabine IH/USP	Manufacturing & Packing
8.	Exemestane BP/USP/Ph.Eur.	Manufacturing & Packing
9.	Lamivudine BP/USP/Ph.Eur.	Manufacturing & Packing
10.	Nevirapine Hemihydrate USP	Manufacturing & Packing
11.	Nevirapine USP	Manufacturing & Packing
12.	Ondansetron Hydrochloride BP/USP/Ph.Eur.	Manufacturing & Packing
13.	Oseltamivir Phosphate BP/USP/Ph.Eur.	Manufacturing & Packing
14.	Tenofovir Alafenamide Fumarate IH	Manufacturing & Packing
15.	Tenofovir Disoproxil Fumarate IH	Manufacturing & Packing
16.	Terbinafine Hydrochloride BP/USP/Ph.Eur.	Manufacturing & Packing

ITEM(s) Sixteen (16) Only

The Written Confirmation remains valid until: 02.07.2028

Chandrashekar Ranga
20/06/25
चंद्रशेखर रंगा/Chandrashekar Ranga
Signature
Joint Drugs Controller (India)
केंद्रीय औषधि नियंत्रक (भारत) / Joint Drugs Controller (India)
C.D.S.C.O (HQ), Dte. General of Health Services
स्वास्थ्य और परिवार कल्याण मंत्रालय / Ministry of Health and Family Welfare
एन.डी.ए. भवन, कोटला रोड, नई दिल्ली-110002 / FDA Bhawan, Kotla Road, New Delhi-110002

Stamp of the authority and date
20 JUN 2025